Thursday, April 30, 2020

A Question on My Recent Webinar on Project Management for FDA Regulated Companies

Query : I'm an informally trained Project Management ... Now I am working on launching product and don't have FDA/EPA experience and we are launching product that falls under either regulation. Would this course (Project Management for FDA regulated companies) be of help?

Ans:  Definitely.  This course focuses on use of simple PM tools to drive FDA projects  (basically PM for the non-PM certified manager).  We cover 3 key tools:  the Gantt Chart (emphasized), the  CPM, and the PERT (with the last two considered for their network, and parallel path illustrative value); also discussing additional tools such as flow charts and cause and effect diagrams to assist in developing Milestones and Tasks.
The projects discussed with sample milestones / templates are:  
  • Design Control (21 CFR 820.30) / Design and Development Planning (ISO 13485:2016 7.3) for new device development; 
  • Product / Process / Equipment / Software Validation; 
  • Product Risk Management (ISO 14971); 
  • Use Engineering / Human Factors Engineering (IEC 62366-1:2015); 
  • Regulatory compliance inspection (Form 483) remediation.  

Due to the short length of the presentations, only the key milestones of each are listed / discussed, but that should be enough to start on the right path to use PM tools in those areas, fleshing out the tasks under the milestones by "reverse engineering", discussed in the webinar.  
Design Control does have an extensive Milestones / tasks listing, but most of the others only focus on Milestones.  
Though not discussed in the webinar, one could take the 21 "tabs" of the FDA's required 510(k) submission to develop the key Milestones for a 510(k) submission as well. 

jel@jelincoln.com

The 21 510(k) "tabs" have been added as project milestones discussed in subsequent versions of my Project Management webinars. - - JEL 09/20/2023

Tuesday, April 14, 2020

Key steps in the validation of the pharmaceutical manufacturing process per US FDA Guidance Document:

Process Validation Guidance Document (Pharma), US FDA,  Jan 2011
  • Stage 1 – Process Design
  • Stage 2 – Qualification
    • Part 1 – Facility Design
    • Part 2 – Qualification of Utilities & Equipment
      • Subsection 1 – Installation Qualification
      • Subsection 2 – Operational Qualification
      • Subsection 3 – Performance Qualification
    • Part 3 – Process Performance Qualification (PPQ)  
  • Stage 3 – Continued Process Verification (ongoing)

John E. Lincoln, jel@jelincoln.com

Friday, January 24, 2020

EO Sterilization Re-validation

If you perform an annual documentation / process review (review of past years' sterile load lot information), with no problems noted, documented, then the following is required every two years, assuming nothing in your process / product has had major changes:
The minimum re-validation requirements of ISO 11135-1:
  • Re-validate PCDs (verify that the ½ cycle BIs are more resistant than product bioburden);
  • Bioburden measurement (should be doing quarterly; no changes in average levels);
  • EO residuals (no subtle changes in product / process / packaging that could increase residuals)
  • 1 Half Cycle (verify overkill)
  • 1 Full Cycle (also used for the EO residuals testing); if acceptable / sterile, can be released for sale.
Also every two years, a full EO validation is required, e.g., 1st year:  Initial full validation, 2nd year:  If OK review, then abbreviated V&V (per above); 3rd year:  full validation; 4th year:  If OK review, then abbreviated V&V (per above); and so on.

John E. Lincoln               jel@jelincoln.com

Tuesday, October 22, 2019



Verification and Validation Webinar - Recent Q&A,   John E. Lincoln,  10/22/2019

Some production-oriented V&V questions:


1.     When it comes to authoring and execution of test protocols, what is my role/responsibly as an automation engineer that has designed and implemented a change to the validated system?  What specifically is validation?

Ans:  You or whoever in your company is responsible for validations must reverify / revalidate whatever has been impacted by the change.  Referencing the original validation, the new V&V would normally not be as extensive as the original, unless the whole equipment / system was changed / replaced.  All based on risk (i.e., the amount of effort / depth) to the ultimate end-user / patient.

I define validation as a series of verifications (tests, checks, inspections) to prove that the item being validated meets its intended purpose(s), as defined by requirements / standards / guidance documents, et al. And there are formal CGMP and ISO definitions which say similar. Those requirements, et al, are changed into test cases which are then run to prove that the requirement exits and has been met, without any negative results.

2.     I noticed in your sample IQ ,OQ, and PQ’s, the evidence collected to prove operational acceptance appears to be strictly signatures.  What is your opinion on screenshots?  If required by validation, whose responsibility (validation, automation, production, etc.) should it be for taking screenshots (collecting evidence)?

Ans:  My definitions:  The IQ is a check list, where each installed requirement / item is checked by a qualified individual (per HR records) who signs off on the presence and functionality of that item on the check list; The OQ is composed of test cases to verify the presence and functionality of each test case based on each requirement ; the PQs (of which there are several depending upon input variables) re-challenge those OQ items / requirements that are subject to further variability by having test cases using sample sizes larger than n=1 (which is the case for OQ test cases); so each PQ has various test cases challenging requirements subject to variability, with each PQ test case using samples of n=30, or 125, etc, per a valid sampling plan based on a solid statistical rationale  (quote / reference a text book, a standard, e.g., Z 1.4, or use an industrial statistician  / consultant).

Screen shots are an excellent tool, and I and others have made much use of them.  However, they must be described in the narrative, may need a unique ID number for each, and each should be signed / initialed and dated, and added to the Test Report.  Responsibility for the screen shots can vary, should be defined by SOP (or the test protocol), but is usually done by those qualified to obtain such and/or who have a vested interest in obtaining them (the one handling the V&V usually). 
 
3.   In your OQ example, you did specify a separation between tester and verifier.  Does this imply that validation should not execute test protocols?  Or is this simply a matter of capability?  I.E. if validation is capable, there is no issue with a computer system validation engineer functioning as a tester?

Ans:  The tester can be the operator, an engineer / tech, or another trained / familiar with the operation being run.  The verifier is often a QC person, not necessarily overly familiar with the specific operation being run (the test case), but who verifies that the instructions in the test case were followed, and the actual achieved results were what were recorded.

4.   In general, it seemed like the focus was on devices, and I’m looking for clarification for where control systems and devices might differ in terms of risk.  For example, on SW V&V Elements – 1, when speaking of LOC (Min, Mod, Maj), you mentioned that Class II device must get elevated to Mod.  How does this relate to software in a data rich control system software environment?  Our systems are primarily Class 4 and 5 software systems (PLC, Operator Interface, Batch Reporting), and for the majority of changes there is little risk to patient or product.  However, because we are modifying Class 4 and 5 systems, it is often hard for us to convince our validation and quality partners that risk is negligible, and they feel their one size fits all approach is therefore justified.

Ans:  The  principle of risk (ultimately to patient / end user) still applies, tho sometimes with some operations its difficult to trace through, that’s why reference to an appropriate ISO 14971 or ICH Q9 Risk Management File is useful.  To somewhat eliminate second-guessing by stake-holders, including gov’t regulatory and internal regulatory, anticipate such push-back, and include an analysis of risk, tied to those files, in your V&V Test Report documentation.  I also try to include such references, tied to specific Risk File line items, with appropriate Test Cases.

"One size fits all" is safest from a bureaucratic standpoint, but is extremely wasteful of resources, and unnecessary.  Your SOPs on V&V should allow some leeway / “trust” in those trained (engineers) to make supported / documented decisions (e.g., I wouldn’t do the degree of effort on a PLC V&V as on a complex software V&V), yet I have done work with companies that required the same level of documentation / approvals for both (painful).

5.   What is your opinion on validation's role when it comes to installing software / firmware patches?  Would it ever be appropriate for IT/Automation to determine the level of risk and be allowed to decide if a log entry is adequate vs determining when full blown change management is required?

Ans:  First, your SOPs must clearly state the methods to be chosen, and how documented.  Second, from a QA standpoint, any patch I feel (my opinion) should be documented by a rev level change.  Unless there’s some identifier in the code, easily accessed.  In other words, there has to be 1) a clear distinction for each change made to the software, 2) changes are themselves V&V’d, approved, including QC/QA, and 3) documented. 

If a log entry is defined by the company as valid, it probably should be supported in documentation somewhere by at least two signatures approving the change.
From a regulatory standpoint, you can’t have one version / release in the field (or in production / manufacturing), but none or few of that version / release are identical to another (sadly another problem I’ve seen). There must be a clear documented history of each. How you as a company chose to work that out (and document for forward / backward traceability) is up to you, subject to the above considerations.

Remember:  I mentioned that this presentation is only one valid approach to V&V, but one that has been field tested, and reviewed by US FDA and EU ISO / Notified-Body inspectors / auditors for over 37 years, with no objections. A company can have another viable and compliant method.

Further considerations:

V&V of production systems generally can have some less depth than device software / firmware - primarily because there are usually redundant checks / verifications "wired" into the production process downstream of a validated item, which are documented in the batch record.  This can also be referenced in the Test Report / Protocol as further justification, similar to patient risk, for degree of effort in a V&V.

-- John E. Lincoln                                                          jel@jelincoln.com

Note:  Para 5 above's reference to the acceptability of a log is geared to the patches to one internal company- / manufacturing-used program, where the log book is a defined part of the change control for a piece of equipment / process.  It does not apply to device / product software or software as a medical device which is distributed to the field / public and would be subject to formal CGMP defined change control for all old and new product in distribution by means of revision / release numbers;  All defined by SOP. - JEL, 02/25/25





Monday, May 13, 2019

   Sources of Medical Device / Equipment Field Use / Quality History

   Ques (heavily redacted) :  I am a South African medical doctor. I have been tasked by the         
   radiology department of one of our hospitals to do a review of medical diagnostic ultrasound 
   systems, specifically if there are studies looking specifically at the quality of the procured equipment 
   from the start.  I came across one of your articles and thought you may have some insights... 

Ans:  I'm not sure what article you're referring to, and the full nature of the assignment with which you've been tasked.  But, it sounds like you are to set up a system to review the quality of ultrasound products the hospital is considering purchasing.  If so, here's some approaches / suggestions: 
1.  ECRI Institute:  https://www.ecri.org/
     I haven't looked at them for many years, but they used to provide analysis like the U.S.'          
     Consumer Reports, but on medical products;
2.  The U.S. FDA:  https://www.fda.gov/
     The FDA maintains a MAUDE (Manufacturer's and Users Device Experience) database,
     which lists products that have been voluntarily reported to have problems (adverse events) in
     the field that could or did cause serious injury or death.  It's not complete, but it can provide
     an idea of field / use issues facing families of products cleared / approved by the FDA.
     You have to get the product's regulation number, by searching the US Federal Register, 21 
     CFR 800-series, and use that number in the MAUDE database.  You can also  search it by 
     common name / description, or manufacturer.  
     New US and EU labeling requirements -- UDI, GUDID (a database), are new but should 
     ultimately provide similar data globally.
3.  Only purchase products from companies following a quality management system, US FDA 
     CGMPs, 21 CFR 820 for devices / equipment, or ISO 13485 / EU MDD / MDR for   
     CE-marked equipment in Europe.  These companies are periodically inspected as to 
     adherence to those respective QMS', which means the equipment meet applicable
     standards / requirements, and were built / documented to required QMS law.

     jel@jelincoln.com

Tuesday, March 26, 2019

ISO 11135:2014 and The QMS

A little more on my answer to the question posed after the EO sterilization webinar:
Ques:  I have a vendor ETO a load for me... what do i need to ensure that they let the load sit or air out between PQ runs?    ISO  11135 or FDA requirement?

Ans:  As mentioned early in the presentation, ISO 11135 presupposes the existence of a viable QMS / CGMP system, as well as adherence to the validation requirements of the standard to complete a successful validation.  Since ISO 11135 is an international standard, it specifically references ISO 13485 requirements under (page 11 of the standard) 4 Quality Management System, 4.1 Documentation, and 4.2 Management Responsibility, and 4.3 Product Realization, et al.   ISO 13485 requires, among others, that a company and its supply chain / vendors adhere to the requirements of 13485 for medical devices.  The US FDA recognizes ISO 11135 as a consensus standard, so for the US, the QSR 21 CFR 820, the CGMPs would be the device QMS in lieu of ISO 13485 (both requirements are very similar).  
So such adherence would assure that your question is addressed.  This can be reaffirmed by a Quality Agreement or Contractual Requirement, verified by Certification / Audit, and/or by other means. 
-- John E. Lincoln     jel@jelincoln.com
A vendor must follow your written requirements/specifications, in this case your validated EO cycle, which also should include a defined minimum aeration time under specified, controlled conditions, all documented, a verified copy of which should be supplied and checked by your QA as part of a sterile load release, all retained in your DHR (lot history).  Since EO gas is a carcinogen, aeration is also a safety requirement.  - JEL, 07/07/25 

The validated aeration time is confirmed by a product's EO residuals data, which have been reviewed and cleared by the FDA as part of a 510(k) clearance or PMA approval. Adherence to a validated sterilization cycle should be clearly stated in the PO, or Contract, or Quality Agreement between the company and the contract sterilizer, and cycle parameters for the lot supplied from the vendor, included with the shipment of sterilized product and checked by the receiving company's QA prior to acceptance at incoming, and prior to final release to the field, and recorded in the DHR for that sterile load, and the individual product lots' DHR's from that sterile load.  - JEL, 08/15/2025